AU2023223808A1 - RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF - Google Patents

RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF Download PDF

Info

Publication number
AU2023223808A1
AU2023223808A1 AU2023223808A AU2023223808A AU2023223808A1 AU 2023223808 A1 AU2023223808 A1 AU 2023223808A1 AU 2023223808 A AU2023223808 A AU 2023223808A AU 2023223808 A AU2023223808 A AU 2023223808A AU 2023223808 A1 AU2023223808 A1 AU 2023223808A1
Authority
AU
Australia
Prior art keywords
compound
cancer
group
pip
fapi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023223808A
Other languages
English (en)
Inventor
Ayaka ASO
Koichi Fukase
Yuichiro KADONAGA
Kazuko Kaneda
Atsushi Shimoyama
Yoshifumi Shirakami
Tadashi WATABE
Taku YOSHIYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of AU2023223808A1 publication Critical patent/AU2023223808A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023223808A 2022-02-22 2023-02-21 RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF Pending AU2023223808A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-026194 2022-02-22
JP2022026194 2022-02-22
PCT/JP2023/006110 WO2023162946A1 (ja) 2022-02-22 2023-02-21 放射標識されたＦＡＰα親和性化合物およびその用途

Publications (1)

Publication Number Publication Date
AU2023223808A1 true AU2023223808A1 (en) 2024-09-19

Family

ID=87765897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023223808A Pending AU2023223808A1 (en) 2022-02-22 2023-02-21 RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF

Country Status (4)

Country Link
EP (1) EP4483905A1 (https=)
JP (1) JPWO2023162946A1 (https=)
AU (1) AU2023223808A1 (https=)
WO (1) WO2023162946A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118388451A (zh) * 2024-06-28 2024-07-26 四川大学 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018312327B2 (en) * 2017-08-04 2022-05-12 Osaka University Production method for radiolabeled aryl compound
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
GB201801882D0 (en) 2018-02-06 2018-03-21 Apollo Tyres Global R & D Bv Rubber composition for tyres with good wet grip and rolling resistance properties
CZ309380B6 (cs) * 2020-03-30 2022-10-26 Ústav organické chemie a biochemie AV ČR v. v. i Sloučeniny pro inhibici fibroblastového aktivačního proteinu
JP7693288B2 (ja) 2020-07-30 2025-06-17 株式会社Ｄｎｐ高機能マテリアル彦根 熱交換器
CN112023064A (zh) * 2020-11-03 2020-12-04 南京大为科创服务有限责任公司 用于标记核素211At的成纤维细胞活化蛋白抑制剂的锡基衍生物及其制备方法和应用

Also Published As

Publication number Publication date
JPWO2023162946A1 (https=) 2023-08-31
EP4483905A1 (en) 2025-01-01
WO2023162946A1 (ja) 2023-08-31

Similar Documents

Publication Publication Date Title
CN115427427A (zh) 一种前列腺特异性膜抗原靶向化合物及其制备方法和应用
WO2019199621A1 (en) Bi-functional molecules to degrade circulating proteins
CN111065646A (zh) 放射性药物
EP4444709B1 (en) Fap-alpha specific tumor diagnostic imaging agent
JP2026500913A (ja) ソマトスタチンサブタイプ－２受容体（ｓｓｔ２ｒ）標的化治療薬及びその使用
EP4378948A1 (en) Radiolabeled compound and use thereof
WO2020053255A1 (en) Therapeutic and diagnostic agents for cancer
AU2023223808A1 (en) RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF
EP4556030A1 (en) Polypeptide compound, and complex and use thereof
KR20250065913A (ko) Rgd 이량체 화합물 및 이의 제조 방법과 응용
EP3959208B1 (en) Cyclen based compounds, coordination compounds, peptides, pharmaceutical preparation, and use thereof
US6995247B2 (en) Ac-HEHA and related compounds, methods of synthesis and methods of use
EP3973999A1 (en) Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
KR101743727B1 (ko) Peg 및 dota 함유 rgd 유도체, 그 제조방법 및 그것을 포함하는 pet 조영제
US20250213735A1 (en) Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
EP4622966A1 (en) Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
CN122003409A (zh) 一类喹啉结构的配体化合物及其放射性或非放射性标记物以及应用
KR101743728B1 (ko) Peg 및 nota 함유 rgd 유도체, 그 제조방법 및 그것을 포함하는 pet 조영제
CN121941696A (zh) 环肽结构的配体化合物及其核素标记物、药物组合物及应用
CN120344273A (zh) 二聚体放射性药物、其组合物及其用途
CN119176854A (zh) 一种多肽类化合物及其配合物、应用
HK40029075A (en) Radioactive drug
CN119176853A (zh) 一种类肽化合物及其配合物、药物组合物和应用
HK1257541B (en) Radiolabeled drug
HK1171022B (en) Smac mimetic